The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies

PAVLASOVÁ, Gabriela, Kateřina MUSILOVÁ, Václav ŠEDA, Kateřina ČERNÁ, Eva VOJÁČKOVÁ, Veronika SVOBODOVÁ and Marek MRÁZ. The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies. In AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer. 2017. ISSN 1535-7163. Available from: https://dx.doi.org/10.1158/1538-8514.SYNTHLETH-A34.

Basic information

• Original name: The identification of combinatorial therapeutic approaches with BCR inhibitors in B cell malignancies
• Authors: PAVLASOVÁ, Gabriela (203 Czech Republic, belonging to the institution), Kateřina MUSILOVÁ (203 Czech Republic, belonging to the institution), Václav ŠEDA (203 Czech Republic, belonging to the institution), Kateřina ČERNÁ (203 Czech Republic, belonging to the institution), Eva VOJÁČKOVÁ (203 Czech Republic, belonging to the institution), Veronika SVOBODOVÁ (203 Czech Republic, belonging to the institution) and Marek MRÁZ (203 Czech Republic, guarantor, belonging to the institution).
• Edition: AACR Precision Medicine Series: Opportunities and Challenges of Exploiting Synthetic Lethality in Cancer, 2017.

Other information

• Original language: English
• Type of outcome: Conference abstract
• Field of Study: 30200 3.2 Clinical medicine
• Country of publisher: United States of America
• Confidentiality degree: is not subject to a state or trade secret
• WWW: URL
• Impact factor: Impact factor: 5.365
• RIV identification code: RIV/00216224:14740/17:00098134
• Organization unit: Central European Institute of Technology
• ISSN: 1535-7163
• Doi: http://dx.doi.org/10.1158/1538-8514.SYNTHLETH-A34
• UT WoS: 000412270800024
• Keywords in English: BCR inhibitor; B cell; CLL
• Tags: rivok

Abstract

It was shown that BCR inhibitors such as ibrutinib interrupt microenvironmental interactions and mobilize malignant B cells of chronic lymphocytic leukemia (CLL) from immune niches into the blood stream. It has been suggested that this mobilization will sensitize malignant B cells to other drugs, providing a possibility to introduce synthetically lethal combinations of drugs with an acceptable toxicity profile. This might be limited to a subgroup of CLL patients with specific underlying molecular mechanisms of disease biology or reaction to BCR inhibitors. The aim of this study was to test for the effect of ibrutinib on the expression of genes and activity of pathways that could be potentially targeted by clinically available drugs to achieve highly potent combinations.

Links

• LQ1601, research and development project: Name: CEITEC 2020 (Acronym: CEITEC2020)

Investor: Ministry of Education, Youth and Sports of the CR